Letropuren

Letrozole, the active ingredient in Letropuren, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone‑receptor‑positive breast cancer in postmenopausal women, both as primary therapy and as adjuvant treatment following surgery.

GNH USA supplies Letropuren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable sourcing for endocrine therapy agents. The company maintains rigorous batch testing, secure packaging, and traceability to ensure product integrity throughout the supply chain.

Letrozole, an aromatase inhibitor, is used in breast cancer management targeting estrogen‑dependent tumor growth.

- Hormone receptor‑positive breast cancer (postmenopausal): reduces tumor recurrence and disease progression. - Adjuvant therapy for early‑stage breast cancer: improves disease‑free survival after surgery. - Metastatic breast cancer (postmenopausal): provides disease control and prolongs survival.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness not relieved by rest. - Nausea: feeling of sickness with or without vomiting.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism: blood clots in veins or lungs. - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Bone fracture: increased risk of osteoporosis‑related fractures. - Myocardial infarction: heart attack due to reduced blood flow. - Anaphylaxis: severe allergic reaction with breathing difficulty.

Before initiating Letrozole therapy, several safety considerations should be addressed.

- Monitor bone density: assess risk of osteoporosis and consider supplementation. - Assess liver function: perform baseline hepatic enzyme tests. - Contraindicated in pregnancy: avoid use in pregnant women (Category X). - Evaluate cardiovascular risk: review history of thromboembolic events. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Letrozole can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Tamoxifen: concurrent use may diminish tamoxifen's therapeutic effect. - Strong CYP3A4 inducers (e.g., rifampin): can lower letrozole plasma concentrations. - Live estrogen therapy: antagonistic action may reduce intended outcomes.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding tendency; monitor INR. - CYP2C19 inhibitors (e.g., fluconazole): may raise letrozole exposure; adjust monitoring.